Prolonged New-Product Development, Commercialization Failures, and Lack of Customer Acceptance
First written in FY2017. 26 of 27 entries say "Restated". Latest entry: FY2025.
The whole theme swung hardest in 2024: 4 of 13 companies on the "Worse" side.
21 other companies' latest entry also says "Restated".
- FY2025RestatedAnnual report
「Cosmetics are products with particularly strong consumer preferences, and even if development proceeds smoothly and a product is commercialized, it may not necessarily be accepted by customers.」
The risks of delays in new-product development, commercialization failures and customer rejection continue. - FY2025-H1RestatedAnnual report
「The filing states that, during the interim consolidated accounting period, there were no material changes in the major risks that management recognizes could materially affect the consolidated companies' financial position, operating results or cash flows, or in the matters described under Business Risks in the securities report for the previous fiscal year.」
It is stated that there have been no material changes in the risks relating to prolonged new-product development, commercialization failures and customer rejection. - FY2024RestatedAnnual report
「Cosmetics are products with particularly strong consumer preferences, and even if development proceeds smoothly and a product is commercialized, it may not necessarily be accepted by customers.」
The risks of delays in new-product development, commercialization failures and customer rejection continue. - FY2024-Q1RestatedAnnual report
「During the cumulative first quarter period, there were no occurrences of major risks that management recognizes as potentially having a material impact on the consolidated companies' financial condition, operating results, or cash flows, among matters related to the business and financial conditions described in the quarterly report, nor were there any material changes to the business and other risks described in the annual securities report for the preceding fiscal year.」
It is stated that there have been no material changes in the risks relating to prolonged new-product development, commercialization failures and customer rejection. - FY2023RestatedAnnual report
「Cosmetics are products with particularly strong consumer preferences, and even if development proceeds smoothly and a product is commercialized, it may not necessarily be accepted by customers.」
The risks of delays in new-product development, commercialization failures and customer rejection continue. - FY2023-Q3RestatedAnnual report
「During the cumulative third quarter period, there were no occurrences of major risks that management recognizes as potentially having a material impact on the consolidated companies' financial condition, operating results, or cash flows, among matters related to the business and financial conditions described in the quarterly report, nor were there any material changes to the business and other risks described in the annual securities report for the preceding fiscal year.」
It is stated that there have been no material changes in the risks relating to prolonged new-product development, commercialization failures and customer rejection. - FY2023-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
No material changes are said to have occurred in the risks relating to prolonged new-product development, commercialization failures and customer rejection. - FY2023-Q1RestatedAnnual report
「During the three-month period ended 30 June, there were no new risks that management recognizes as having the potential to materially affect the financial position, operating results or cash flows of the consolidated companies, and no material changes to the business risks described in the annual securities report for the previous fiscal year.」
It is stated that there have been no material changes in the risks relating to prolonged new-product development, commercialization failures and customer rejection. - FY2022RestatedAnnual report
「Even if development proceeds smoothly and a product is commercialized, it may not necessarily be accepted by customers.」
The risks of delays in new-product development, commercialization failures and customer rejection continue. - FY2022-Q3RestatedAnnual report
「During the nine-month period of the current consolidated fiscal year, there were no occurrences of the principal risks that management recognised as potentially having a material impact on the financial condition, operating results or cash flows of the consolidated companies, and no material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year, among the matters relating to the business and accounting conditions described in the quarterly report.」
No material changes are said to have occurred in the risks relating to prolonged new-product development, commercialization failures and customer rejection. - FY2022-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
No material changes are said to have occurred in the risks relating to prolonged new-product development, commercialization failures and customer rejection. - FY2021RestatedAnnual report
「Even if development proceeds smoothly and a product is commercialized, it may not necessarily be accepted by customers.」
The risks of delays in new-product development, commercialization failures and customer rejection continue. - FY2021-Q3RestatedAnnual report
「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
No material changes are said to have occurred in the risks relating to prolonged new-product development, commercialization failures and customer rejection. - FY2021-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
No material changes are said to have occurred in the risks relating to prolonged new-product development, commercialization failures and customer rejection. - FY2021-Q1RestatedAnnual report
「During the three-month period ended 30 June, there were no new risks that management recognizes as having the potential to materially affect the financial position, operating results or cash flows of the consolidated companies, and no material changes to the business risks described in the annual securities report for the previous fiscal year.」
No material changes are said to have occurred in the risks relating to prolonged new-product development, commercialization failures and customer rejection. - FY2020RestatedAnnual report
「Even if development proceeds smoothly and a product is commercialized, it may not necessarily be accepted by customers.」
The risks of delays in new-product development, commercialization failures and customer rejection continue. - FY2020-Q3RestatedAnnual report
「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
No material changes are said to have occurred in the risks relating to prolonged new-product development, commercialization failures and customer rejection. - FY2020-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
No material changes are said to have occurred in the risks relating to prolonged new-product development, commercialization failures and customer rejection. - FY2020-Q1RestatedAnnual report
「During the first three months of the consolidated fiscal year, there were no material changes concerning matters described in the quarterly securities report that could materially affect investors' decisions, or to the business and other risks described in the securities report for the previous fiscal year.」
No material changes are said to have occurred in the risks relating to prolonged new-product development, commercialization failures and customer rejection. - FY2019-Q3RestatedAnnual report
「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
No material changes are said to have occurred in the risks relating to prolonged new-product development, commercialization failures and customer rejection. - FY2019-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
No material changes are said to have occurred in the risks relating to prolonged new-product development, commercialization failures and customer rejection. - FY2019-Q1RestatedAnnual report
「During the first three months of the consolidated fiscal year, there were no material changes concerning matters described in the quarterly securities report that could materially affect investors' decisions, or to the business and other risks described in the securities report for the previous fiscal year.」
No material changes are said to have occurred in the risks relating to prolonged new-product development, commercialization failures and customer rejection. - FY2018RestatedAnnual report
「Even if development proceeds smoothly and a product is commercialized, it may not necessarily be accepted by customers.」
The risks of prolonged R&D, additional investment, commercialization failures and the possibility that products will not be accepted by customers continue to be stated. - FY2018-Q3RestatedAnnual report
「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
No material changes are said to have occurred in the risks relating to prolonged new-product development, commercialization failures and customer rejection. - FY2018-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
No material changes are said to have occurred in the risks relating to prolonged new-product development, commercialization failures and customer rejection. - FY2018-Q1RestatedAnnual report
「During the first three months of the consolidated fiscal year, there were no material changes concerning matters described in the quarterly securities report that could materially affect investors' decisions, or to the business and other risks described in the securities report for the previous fiscal year.」
No material changes are said to have occurred in the risks relating to prolonged new-product development, commercialization failures and customer rejection. - FY2017First statedAnnual report
「Even if development proceeds smoothly and a product is commercialized, it may not necessarily be accepted by customers.」
The company identifies as risks the effects of prolonged R&D, additional investment, failure to commercialize products and products not being accepted by customers.